Thomas Hartung's Biography

Thomas Hartung, Professor and Doerenkamp-Zbinden Chair for Evidence-based Toxicology, Director of the Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health

Thomas Hartung, MD PhD, is the Doerenkamp-Zbinden-Chair for Evidence-based Toxicology in the Department of Environmental Health and Engineering at Johns Hopkins Bloomberg School of Public Health, Baltimore, with a joint appointment at the Whiting School of Engineering. He also holds a joint appointment for Molecular Microbiology and Immunology at the Bloomberg School. He is adjunct affiliate professor at Georgetown University, Washington D.C.. In addition, he holds a joint appointment as Professor for Pharmacology and Toxicology at University of Konstanz, Germany; he also is Director of Centers for Alternatives to Animal Testing (CAAT, http://caat.jhsph.edu) of both universities. CAAT hosts the secretariat of the Evidence-based Toxicology Collaboration (http://www.ebtox.org), the Good Read-Across Practice Collaboration, the Good Cell Culture Practice Collaboration, the Green Toxicology Collaboration and the Industry Refinement Working Group. As PI, he headed the Human Toxome project funded as an NIH Transformative Research Grant. He is Chief Editor of Frontiers in Artificial Intelligence. He is Consulting Vice-President of AxoSim Inc., New Orleans. He is the former Head of the European Commission’s Center for the Validation of Alternative Methods (ECVAM), Ispra, Italy, and has authored more than 585 scientific publications.

Three Things Count for MPS and Organoids: Quality, Quality and Quality!

Tuesday, 29 June 2021 at 16:30

Add to Calendar ▼2021-06-29 16:30:002021-06-29 17:30:00Europe/LondonThree Things Count for MPS and Organoids: Quality, Quality and Quality!3D-Culture, Organoids and Organ-on-a-Chip Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

The promise of the novel cell culture technologies (microphysiological systems, MPS, including organ-on-chip models ad organoids) replicating organ architecture and function is counterbalanced by the demanding technologies, efforts and costs, often limiting throughput and number of replicates. With increasing desire to use them also in the regulatory context, the quality of work comes into focus. The first quality concerns the fidelity of the model in replicating (patho-)physiology and relevant responses. This is typically addressed by validation, but the complexity of models and responses requires an adaptation of the validation process. The second quality refers to the quality of performance of the work. In the regulatory context, Good Laboratory Practice (GLP) and the associated Good In Vitro Method Practice (GIVIMP) still require adaptation to MPS. Good Cell Culture Practice (GCCP), which is more geared toward defining minimum standards also applicable in non-GLP environments, is undergoing already such adaptations and with stakeholder review on the way, GCCP 2.0 is expected to be finalized later in 2021. The third quality refers to the quality of reporting. Two initiatives, i.e., the In Vitro Critical Appraisal Tool (IV-CAT) and Good In Vitro Reporting Standards (GIVReSt) are on the way. Together with organizations like the US Food and Drug Administration (FDA) defining their performance standards, these quality assurance and control initiatives pave the way for relevant, reproducible science and maximum impact of MPS technologies. The 2022 MPS World Summit aims to foster these quality initiatives also with the planned creation of an International society.

Add to Calendar ▼2021-06-28 00:00:002021-06-30 00:00:00Europe/London3D-Culture, Organoids and Organ-on-a-Chip Europe 20213D-Culture, Organoids and Organ-on-a-Chip Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors